Analystreport

Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report